Kinexa 10
- Kinexa is an effective anticoagulant for managing various thromboembolic conditions.
- Formulations: Available in 2.5 mg, 10 mg, and 20 mg doses.
- Indications: Prevents and treats atherothrombotic events after acute coronary syndrome, reduces stroke risk in atrial fibrillation, and manages deep vein thrombosis and pulmonary embolism.
- Active Ingredient: Rivaroxaban, a direct factor Xa inhibitor, prevents clot formation.
- Administration: Proper dosing and monitoring are crucial for maximizing efficacy and minimizing risks.
Kinexa 15
- Kinexa is an effective anticoagulant for managing various thromboembolic conditions.
- Formulations: Available in 2.5 mg, 10 mg, and 20 mg doses.
- Indications: Prevents and treats atherothrombotic events after acute coronary syndrome, reduces stroke risk in atrial fibrillation, and manages deep vein thrombosis and pulmonary embolism.
- Active Ingredient: Rivaroxaban, a direct factor Xa inhibitor, prevents clot formation.
- Administration: Proper dosing and monitoring are crucial for maximizing efficacy and minimizing risks.
Kinexa 2.5
- Kinexa is an effective anticoagulant for managing various thromboembolic conditions.
- Formulations: Available in 2.5 mg, 10 mg, and 20 mg doses.
- Indications: Prevents and treats atherothrombotic events after acute coronary syndrome, reduces stroke risk in atrial fibrillation, and manages deep vein thrombosis and pulmonary embolism.
- Active Ingredient: Rivaroxaban, a direct factor Xa inhibitor, prevents clot formation.
- Administration: Proper dosing and monitoring are crucial for maximizing efficacy and minimizing risks.
Kinexa 20
- Kinexa is an effective anticoagulant for managing various thromboembolic conditions.
- Formulations: Available in 2.5 mg, 10 mg, and 20 mg doses.
- Indications: Prevents and treats atherothrombotic events after acute coronary syndrome, reduces stroke risk in atrial fibrillation, and manages deep vein thrombosis and pulmonary embolism.
- Active Ingredient: Rivaroxaban, a direct factor Xa inhibitor, prevents clot formation.
- Administration: Proper dosing and monitoring are crucial for maximizing efficacy and minimizing risks.